Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer
In this article
Systematic Review & Meta-analysis — JAMA Oncology 2025
Published September 11, 2025 — JAMA Oncology
🧩 Can PROs Predict Survival?
Prognosis usually relies on stage, labs, imaging. Yet patient-reported outcomes (PROs)—covering symptoms, quality of life, functional status— provide independent and additive prognostic value for overall survival.
📋 What Are PROs?
Health data reported directly by patients: symptoms, QoL, functional capacity, daily activities. Captures the patient’s perspective beyond clinician-rated scales.
- Tablet/Kiosk at intake
- Mobile apps (daily/weekly check-ins)
- SMS/Email short forms w/ reminders
- Web portals for QoL & adverse events
Typical cadence: baseline, each visit, and every 1–4 weeks.
🧠 How ePROs Are Used
In trials, PROs quantify treatment impact. In clinics, they act as an early-warning system to trigger supportive care and timely interventions.
Figure: Patients submit ePROs → central PRO system → alerts & dashboards for the care team.
🚀 Quick Summary
- Global Health/QoL: each +1 point → ~1% lower mortality (HR 0.99)
- Symptoms linked with poorer OS: Nausea/vomiting (HR 1.12), pain (1.07), fatigue (1.05), appetite loss (1.04), dyspnea (1.03)
🧪 Methods — Evidence Base
- Design: Systematic review of RCTs (2000–2024); meta-analysis of 31 studies
- Population: Adults; major types: lung (20%), head & neck (12%), pancreas (12%), colorectal (10%), prostate (10%)
- Measures: Baseline PROs (incl. EORTC QLQ-C30); outcome: overall survival (OS)
- Stats: Multivariable adjustment; random-effects pooling; Egger’s test (no significant bias)
📊 Key Findings — Hazard Ratios & Interpretation
| PRO Domain | Pooled HR (95% CI) | Clinical Meaning |
|---|---|---|
| Physical functioning | 0.94 (0.92–0.96) | Higher scores → ~6% lower mortality |
| Role functioning | 0.96 (0.94–0.98) | Maintaining roles correlates with better OS |
| Global health / QoL | 0.99 (0.98–0.99) | Each +1 point → ~1% lower mortality |
| Nausea / vomiting | 1.12 (1.04–1.21) | Higher severity ↑ risk (~+12%) |
| Pain | 1.07 (1.04–1.11) | Uncontrolled pain ↔ worse OS |
| Fatigue | 1.05 (1.00–1.10) | Severe fatigue = higher mortality |
| Appetite loss | 1.04 | Likely via malnutrition effect |
| Dyspnea | 1.03 | Symptom control is critical |
| Constipation / Insomnia | — | No significant association |
🎯 Clinical Implications — PROs as “Missing Variables”
At similar disease stages, patients with stronger baseline physical/role function often live longer. Integrate PROs into risk stratification & decision-support.
High symptom scores → early supportive care (nutrition, PT, pain)
Embed baseline PRO panels & auto-alerts in EHR dashboards
Stratify & adapt monitoring using PRO-defined risk
🛠️ Five Practical Implementation Steps
- Baseline screening: EORTC QLQ-C30 short form at first visit
- Thresholds: Physical/role <50 → early referrals (nutrition, PT, pain clinic)
- Digital monitoring: Monthly SMS/app surveys + automated call reminders
- Dashboards: Highlight “PRO red flags” (↑ pain, ↑ nausea, ↑ fatigue)
- Reporting: Add PRO trend graphs to every visit summary (with before/after views)
⚠️ Limitations
- Heterogeneity in designs, populations, cancer types
- RCT cohorts may be more selective than real-world
- “Strongest” PRO predictor not rankable (overlapping CIs)
🔭 Future Perspective
The fusion of biology + patient experience is the next standard in oncology. PRO-driven tools will sharpen survival prediction and strengthen patient-centered care.
Reference: Huang RS et al., JAMA Oncology, online Sept 11, 2025. DOI: 10.1001/jamaoncol.2025.3153.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.